AssetMark Inc
KYMR icon

AssetMark Inc’s Kymera Therapeutics KYMR Stock Holding History

AssetMark Inc’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917 Hold
8
– – ﹤0.01% 3164
2026
Q1 		$666 Buy
8
+2
+33% +$158 ﹤0.01% 3124
2025
Q4 		$467 Hold
6
– – ﹤0.01% 3114
2025
Q3 		$340 Hold
6
– – ﹤0.01% 2983
2025
Q2 		$262 Buy
+6
New +$207 ﹤0.01% 2842

Other funds holding KYMR

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

AssetMark Inc's KYMR Position: Q2 2026 in Review

AssetMark Inc held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 8 shares worth $917. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

AssetMark Inc first reported a position in KYMR in Q2 2025 and has held it in 5 quarters since. 81 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • AssetMark Inc held 8 shares of Kymera Therapeutics worth $917 as of Q2 2026.
  • AssetMark Inc left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3164 holding.
  • AssetMark Inc first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 81 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.